Back to search results

Imaging Brain Metastasis with 18F-FLUC PET/MR

This study is looking at new ways to image brain metastases (cancers that have spread to the brain). It uses a special imaging method called PET/MRI with a tracer called F-Fluciclovine to see if it can find cancerous tissue better than current imaging methods. The study wants to see how much amino acid (a building block of proteins) is taken up by the tumor tissue. You might be able to join if you are 18 or older, have a brain metastasis, have had radiation therapy in the last two years, and are currently or have been treated with other systemic therapies. The study is currently unclear on its recruitment status and plans to enroll 30 participants.

Study design
This is an interventional study with a planned enrollment of 30 participants. It is not specified if it is randomized or blinded.
What's involved
You will have a single PET/MRI scan, followed by a separate MRI scan with a tracer. Your participation will last about 3 hours.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06159335

18F-FLUC PET/MR in Patients With Brain Mets

Recruiting
PHASE3Ages 18+InterventionalDiagnostic
University of Wisconsin, Madison
~30 participants
Updated 2026-06-22 on ClinicalTrials.gov
What's tested:F-Fluciclovine radiotracer

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Amino acid uptake into tumor tissue
Measured over 3 hours

Conditions

Brain Metastasis
Radiation Therapy
Immunotherapy, Active

Explore related trials

Metastatic Malignant Neoplasm in the Brain

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Michael Veronesi, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Wisconsin, Madison

Who to contact

Radiology Studies
[email protected]
608-282-8349
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Able and willing to provide informed consent
Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
Received radiation therapy at some point in the last 2 years
Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy, immunotherapy, or chemotherapy following radiation therapy.
Patients are eligible for the study if their most recent standard-of-care MRI, used to assess disease location and extent, raises the question of tumor recurrence versus treatment-related changes. This concern can be noted by the radiologist or other members of the multidisciplinary care team, such as during a multidisciplinary conference. Additionally, if there are clinical concerns based on evolving exam findings or symptoms, and the treating physician suspects progression versus treatment-induced changes, the patient is also eligible for the study.
Be able to lie still for 30-60 minutes during the imaging procedure
Willing and able to undergo PET/MRI or PET/CT
Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
The subject has their own prescription for the medication
The informed consent process is conducted prior to the self-administration of this medication
They come to the research visit with a driver

Exclusion

Subject unable or unwilling to provide informed consent
Subject is pregnant
Subject with contraindication(s) to or inability to undergo a PET/MR or PET/CT
Known allergy to 18F-Fluciclovine or any of its excipients

What this trial measures

  • Amino acid uptake into tumor tissue3 hours

    Using 18F-Fluciclovine PET, compare amino acid uptake into brain tumor tissue with uptake in normal brain tissue. Higher uptake is hypothesized to indicate malignancy